@article{3089952,
    title = "Comparative immunohistochemical analysis of aurora-A and aurora-B expression in human glioblastomas. Associations with proliferative activity and clinicopathological features",
    author = "Samaras, V. and Stamatelli, A. and Samaras, E. and Arnaoutoglou, C. and Arnaoutoglou, M. and Stergiou, I. and Konstantopoulou, P. and Varsos, V. and Karameris, A. and Barbatis, C.",
    journal = "PATHOLOGY RESEARCH AND PRACTICE",
    year = "2009",
    volume = "205",
    number = "11",
    pages = "765-773",
    issn = "0344-0338",
    doi = "10.1016/j.prp.2009.06.011",
    keywords = "aurora A kinase;  aurora B kinase;  carmustine;  Ki 67 antigen;  temozolomide, adult;  aged;  antigen expression;  article;  cancer combination chemotherapy;  cancer radiotherapy;  cancer surgery;  cancer survival;  cell proliferation;  clinical article;  female;  glioblastoma;  histopathology;  human;  human tissue;  immunohistochemistry;  immunoreactivity;  male;  multiple cycle treatment;  primary tumor;  prognosis;  protein function;  survival time;  tumor localization, Adult;  Aged;  Aged, 80 and over;  Analysis of Variance;  Brain Neoplasms;  Cell Proliferation;  Cerebral Cortex;  Combined Modality Therapy;  Female;  Glioblastoma;  Humans;  Immunohistochemistry;  Kaplan-Meiers Estimate;  Ki-67 Antigen;  Male;  Middle Aged;  Protein-Serine-Threonine Kinases;  Statistics, Nonparametric;  Treatment Outcome",
    abstract = "In the present study, we carried out a comparative immunohistochemical analysis of aurora-A and aurora-B expression in 40 patients with primary glioblastomas, and attempted to identify any associations with Ki-67 index and the patients' clinical features. The impact of various treatment modalities and proliferative activity on patient outcome was also assessed. Immunohistochemistry was carried out using formalin-fixed and paraffin-embedded tissue sections. Aurora-A expression was higher in tumors with high Ki-67 expression (p=0.01) and was positively, though marginally, related to aurora-B expression (p=0.085). Aurora-B expression was not linked to Ki-67 expression (p=0.182). Lower aurora-A immunohistochemical expression, chemotherapy administration, and tumor localization in one lobe of the brain implied a greater probability of patient survival in univariate analysis (p=0.044, p=0.008, p=0.041, respectively). Ki-67 and aurora-B immunoreactivities were not associated with patient survival (p=0.918 and p=0.539, respectively). To our knowledge, for the first time, the association between aurora-A and aurora-B expression, the correlation of aurora-A with Ki-67 index, and the prognostic impact of aurora-A expression were assessed in glioblastomas. Although we addressed a prognostic connotation of aurora-A, we presume that aurora-A and aurora-B play a complicated role within glioblastomas. Further examinations of larger series are required, so that definite conclusions can be drawn. © 2009 Elsevier GmbH. All rights reserved."
}